MYCO-007

**MYCO-007** is a short-acting **MDMA analogue** and **entactogen** under development for the treatment of **psychiatric disorders**. Developed by **Mydecine Innovations Group**, it belongs to a family of patent-pending second-generation **MDMA analogs** (MYCO-005, MYCO-006, MYCO-007) designed to improve upon the pharmacokinetic profile of MDMA with potentially shorter duration of action while retaining therapeutic entactogenic effects. The program targets mental health conditions such as **post-traumatic stress disorder (PTSD)** and **nicotine addiction**, leveraging the empathogenic properties of MDMA-like compounds in a psychedelic-assisted therapy context.[1][5][9][11]